ASXL1 and Myelodysplasia: A major change in the 2022 ELN classification was the addition of seven myelodysplasia-related gene mutations (in the BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1 and ZRSR2 genes) to the ASXL1, RUNX1 and TP53 mutations already included in the 2017 ELN classification as criteria for adverse group assignment, unless they co-exist with “favorable-risk AML subtypes” [26].